Abstract

Hepatitis B virus (HBV) reactivation is a serious but preventable complication of immunosuppression. Chemotherapy in patients with lymphoma without specific anti-HBV prophylaxis leads to significant impairment of liver function and results in an overall liver-related mortality of greater than 5%. Prevention is a better approach than intervention at the time of reactivation. The cause of death is usually HBV-related fulminant liver failure. We reported a case of a male patient aged 42 years old who was present with acute liver failure related to chemotherapy for treatment of gastric lymphoma. He was later known as having chronic carrier hepatitis B, with high elevated transaminases and hyperbilirubinemia and signs of decompensated liver. The patient was admitted to High Care Unit for best supportive care but his condition was deteriorating and eventually died eventhough he had been already given antiviral agent.

Links

Publisher Full Text

Authors

Wijaya I, Sanityoso A, Lesmana LA

Institution

Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo Hospital. Jl. Diponegoro no. 71, Jakarta Pusat 10430, Indonesia. leon_natan@yahoo.com

Source

Acta medica Indonesiana 44:2 2012 Apr pg 145-9

MeSH

Adult
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Doxorubicin
Fatal Outcome
Hepatitis B virus
Hepatitis B, Chronic
Humans
Liver Failure, Acute
Lymphoma, Non-Hodgkin
Male
Prednisone
Stomach Neoplasms
Vincristine
Virus Activation

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

22745146